Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

Tumble51 Oct. 7 at 11:16 AM

$AGIO Sure Steve Hoerter , who came from this sihthole, to ruin DCPH in Mass. I warned people !! Matt Kapusta at QURE…an ex stock broker , no skill set Remi Barbier from $SAVA ..walked off the property by the DOJ Tardugno, the guinea from $IMNN , failure , changed the name Choung an ex Pfizer man at $BIVI , running that into the ground List is endless Schenkien from Agios , bold face liar Fouse , ex Celgene exec. , ruined Bunge (BG) in her time there Now COB at AGIO The it’s just keep on coming John Maraganore LEFT AGIO, due to incompetence on the senior level, was CEO of ALNY , rocketed it to HUGE SUCCESS

0 · Reply

JasonRKT Oct. 6 at 10:45 PM

$IMNN looks like it go below $16 tomorrow 😔

1 · Reply

Groggok Oct. 6 at 9:29 PM

$IMNN Doesn’t take much to rally like $ SPRB. https://finance.yahoo.com/m/6a98c8b9-fc5d-3360-8e12-3853908c3d7a/why-spruce-biosciences-just.html

1 · Reply

ConcernedCitizen23 Oct. 6 at 7:06 PM

$SPRB this condition is tiny…ovarian cancer is much more common. $IMNN is in phase 3 for ovarian cancer

0 · Reply

Thespartantrades Oct. 6 at 5:16 PM

$VRCA $IMNN $PC $CNSP Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.

0 · Reply

ConcernedCitizen23 Oct. 5 at 10:42 PM

$IMNN https://investors.imunon.com/news-releases/news-release-details/imunon-participate-hc-wainwright-27th-annual-global-investment

1 · Reply

ConcernedCitizen23 Oct. 5 at 10:42 PM

$IMNN the last two minutes of this investor webcast are very interesting…”we have been approached by potential partners”. “We will present more data at highly regarded meetings and publications”, “enough money well into 4th quarter”

1 · Reply

jjegglie Oct. 5 at 8:02 PM

$IMNN A stock promotion scam corporation using the exact same approach they always have to steal shareholder money. Down 99.99999% from all time highs. Target price: $0

0 · Reply

parabolic_guy Oct. 5 at 7:41 AM

$IMNN Biotech with novel approach. Chart shows distribution pattern. Avoid until base formation completes.

0 · Reply

TheManUpstairs Oct. 3 at 8:32 PM

$IMNN me @ 5,3x

0 · Reply

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Sep 19, 2025, 8:05 AM EDT - 17 days ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

Aug 28, 2025, 8:05 AM EDT - 5 weeks ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 2 months ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 2 months ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 2 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 2 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 2 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 2 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 2 months ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 2 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 3 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 4 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 4 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 4 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 4 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 5 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 5 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 5 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 5 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 5 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 5 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 6 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 7 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 7 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 7 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 7 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 8 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 8 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 8 months ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 10 months ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 10 months ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Nov 25, 2024, 8:05 AM EST - 11 months ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 7, 2024, 5:11 PM EST - 11 months ago

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:00 AM EST - 11 months ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Nov 7, 2024, 8:05 AM EST - 11 months ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 31, 2024, 8:30 AM EDT - 1 year ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

Oct 30, 2024, 9:05 AM EDT - 1 year ago

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Oct 7, 2024, 8:05 AM EDT - 1 year ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2024, 4:06 PM EDT - 1 year ago

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Aug 28, 2024, 8:30 AM EDT - 1 year ago

IMUNON to Host R&D Day on September 18th

Aug 14, 2024, 2:55 PM EDT - 1 year ago

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 7, 2024, 5:04 PM EDT - 1 year ago

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Jul 30, 2024, 1:07 PM EDT - 1 year ago

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Jul 30, 2024, 9:42 AM EDT - 1 year ago

Imunon's stock rockets after ovarian cancer treatment's positive trial results

Jul 30, 2024, 8:00 AM EDT - 1 year ago

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

Tumble51 Oct. 7 at 11:16 AM

0 · Reply

JasonRKT Oct. 6 at 10:45 PM

$IMNN looks like it go below $16 tomorrow 😔

1 · Reply

Groggok Oct. 6 at 9:29 PM

$IMNN Doesn’t take much to rally like $ SPRB. https://finance.yahoo.com/m/6a98c8b9-fc5d-3360-8e12-3853908c3d7a/why-spruce-biosciences-just.html

1 · Reply

ConcernedCitizen23 Oct. 6 at 7:06 PM

$SPRB this condition is tiny…ovarian cancer is much more common. $IMNN is in phase 3 for ovarian cancer

0 · Reply

Thespartantrades Oct. 6 at 5:16 PM

0 · Reply

ConcernedCitizen23 Oct. 5 at 10:42 PM

$IMNN https://investors.imunon.com/news-releases/news-release-details/imunon-participate-hc-wainwright-27th-annual-global-investment

1 · Reply

ConcernedCitizen23 Oct. 5 at 10:42 PM

1 · Reply

jjegglie Oct. 5 at 8:02 PM

$IMNN A stock promotion scam corporation using the exact same approach they always have to steal shareholder money. Down 99.99999% from all time highs. Target price: $0

0 · Reply

parabolic_guy Oct. 5 at 7:41 AM

$IMNN Biotech with novel approach. Chart shows distribution pattern. Avoid until base formation completes.

0 · Reply

TheManUpstairs Oct. 3 at 8:32 PM

$IMNN me @ 5,3x

0 · Reply

TheManUpstairs Oct. 3 at 8:31 PM

$IMNN bigger resistance around 5,6ish... so i´m curious

0 · Reply

I_AM_GROOT Oct. 3 at 8:02 PM

$IMNN Too bad they missed a good cash raise window at $9.00. They still need 50 mill to complete phase 3. This is going to hurt real bad if they drop 10 million shares.

1 · Reply

Vikingsstrade Oct. 3 at 5:55 PM

$IMNN $PC $GBIO $CNSP Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

kshonstocks Oct. 3 at 2:26 PM

$IMNN hitting scans an off the bottom pattern

1 · Reply

Skies88 Oct. 2 at 8:22 PM

$IMNN $SMLR

0 · Reply

ConcernedCitizen23 Oct. 2 at 5:21 PM

$IMNN I hope people realize the risk/reward here…we are actively in phase 3 here at $13MILLION market cap…it could go to zero of course or go to $500MILLION easily which would be a 40x from here. That’s how I think about it.

1 · Reply

AZOZ Oct. 2 at 2:03 PM

$IMNN Loading zone 👀

0 · Reply

Skies88 Sep. 29 at 4:14 PM

$SMLR $HOLO $IMNN

0 · Reply

AZOZ Sep. 29 at 11:11 AM

$IMNN Double bottom Stay tuned!

2 · Reply

ConcernedCitizen23 Sep. 25 at 4:04 PM

$IMNN I hope people realize how special it is to have a nice cancer treatment starting phase 3 (several patients enrolled based on latest PR) trading for $12 million?!? Omg I’ll buy more soon if it doesn’t 10x

1 · Reply

BidAxe Sep. 25 at 2:12 PM

$IMNN I'm a little foggy, because I jumped ship on the last pump. How long has it been since the last offering?I'm smelling a PR pump and a dilution dump on the horizon.

2 · Reply

Steve_Rose Sep. 25 at 12:34 PM

$IMNN NXXT trucks technology and customers came in house overnight via Yoshi and Shell deals scaling like a seasoned operator not a startup

0 · Reply

Market Cap	13.10M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	116,800
Avg Vol	169,854
Day's Range	N/A - N/A
Shares Out	2.44M
Stochastic %K	40%
Beta	2.22
Analysts	Strong Sell
Price Target	$25.09